Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would a defense lawyer be an ASCO member and have 3 assistants with them?
I really can’t say definitively that naked shorts exist, but I have noticed a trend in similar microcap biotechs, where unexpected positive news triggers a massive buying volume, indicating Larry Smith’s naked short hypothesis has merit. In some cases, I’ve noticed that buy volume immediately after positive news exceeds the outstanding float. This lends credit to the naked short theory.
The May FINRA report indicates that roughly 70% of the volume here was shorted in that trading month. I calculated that to be about 15-20 million shares shorted in May 2019 alone.
I guess we’ll see what happens after topline data is announced. If negative, the shorts rejoice. If positive...???
Seems like a VERY dangerous game to be shorting a security with NWBOs potential at .30. I wonder if the short side is already in so deep that they have no choice but to keep it going and hope for the topline binary event to rescue them.
Everyone (even our management) agrees that it’s been almost a miracle that NWBO has survived to get to their topline data in this phase 3 trial. Positive data could ignite some real fireworks.
Who doesn’t appreciate an epic squeeze? It’s like a big hug for those shorts.
He did say that. He said he’s invested. He has friends invested. They all have their money where their mouth is.
Cofer was a character. I thanked him for his service to our country. I can’t imagine what his experiences were with the CIA.
I was there with the alpha ??.
I met with Innes, Les, Cofer, and Dr. Ashkan.
My question to Dr. Ashkan centered around whether there were any improvements in SOC that he may have noticed in GBM in the last 10 years due to surgery. He wasn’t aware of any. His comment back was...”you always think you get it all, but you never get it all”. I’ve heard that before from other surgeons.
Cofer acknowledged that he sees what we all see with naked shorts. But, as we’re all aware, they’re wicked smart and they hide their actions well. Probably worse than terrorists. I concur with Smith on Stocks assessment. We have to accept them as part of the investment equation. If the data is positive, the short squeeze could be epic.
Innes has been consistent in his guesstimate that topline will come later this summer. The final data will be what it is, but the indications of success are there.
Dr. Ashkan was direct in that he believes that this is a therapy that works for his patients and he is standing alongside the company because of what he sees in his practice. He is well respected and has earned his reputation as a leading surgeon in Europe. I was humbled to speak with him.
I spent very little time with Les. He was cordial and his comments were consistent with what beartrap and Ikeesq have shared from previous shareholder meetings. He’s not in this for the money. He’s in this for the purpose. They all are and they’ve been hardened by battle.
I’m hoping topline gives them some redemption. We’re close and will make it to the finish line. Everyone’s disposition reflected that.
The big question about project facilitate is whether the company can charge for the drug. If not, project facilitate might as well be project over.
That is an interesting piece of information alpha. Could there possibly be negotiations going on with Big Pharmas that are requiring the SAP to be delayed from submission? Perhaps a big company looking to acquire them is asking to be allowed to submit the SAP after they’ve been bought out.
We all know that the Sawston deal took bankruptcy off the table. The Cognate deal put moving forward back in the table. The L data is still overwhelmingly positive. Direct is coming. I imagine that BP has noticed this too. This could be the last chance to buy in with a discount. Once NWBO data is revealed, if it’s good...it’s game over. And there is always somebody willing to take a risk with this type of potential reward.
I’m not saying it’s a done deal. I’m saying that it’s a possibility.
This could be “reading between the lines”.
According to FINRA, short volume was 60-80% of the total May volume? That’s playing with fire. Who wrote that trading algorithm code?
Better check it on a line by line basis. The burn may come on Monday.
This isn’t a new drug. This is a technology and platform with the potential to turn an existing 100 billion dollar industry upside down. Dave Innes has every reason to be excited. Imagine what happens if we duplicate results on other solid tumors and combine this vaccine with other immune agents to enhance its effectiveness. If proven effective, big money will flow in, analysts and funds will get interested, and shorts will be forced to find another micro cap to bully.
We do. The Alphapuppy is there.
I see LP in the background there rejecting Pfizer’s 8 billion dollar offer. Too low. Try again.
Well said. In the end, the convergence of the financial and humanitarian interest in this security has always been the beauty to me. Thanks for sipping on the Kool Aid with us.
I’m ok with making some money in the drug business. Less meth, more GBM cures.
If you’re nice, I’ll tell you which storage units work best to stash your cash.
Hahaha... now let’s all enjoy this ride together.
Young cancer doctors = egomaniacs. Must teach that in residency these days. Glad you studied up on your immunotherapy. Now go pass your boards.
Somebody has to sell at $2 for it to be worth that. With positive data, little debt, and imminent approval on the horizon...good luck finding shares at $2.
Wasn’t today’s announcement representative of 40 million potential dilutive shares being brought back in under company control? Do you understand how dilutions work?
This is great news!!! 40 million potential diluted shares now gone and they can move forward with new production.
A PR is coming. It could be next week or next month. This isn’t the time to be selling shares.
No doubt this is a binary proposition. Either the folks at NWBO are a bunch of liars or they have a significant development in the fight against cancer. If the latter is the case, UCLAs team will have quite the awards season. Marzans minions will enjoy watching from their luxury suite.
100 days until the start of college football season. We’ll have topline data by then. I like UCLA this season.
A few pennies and a few months aren’t the endgame here. I’m sticking around for combo trials, approvals, partnerships, etc. Buyout is endgame. In the end, if BP is forced to pony up the big billions, they will.
Your minions? Are these the little yellow guys in overalls that you cruise with?
It’s long gone...haha.
Don’t count on topline at ASCO. It will come when it comes. Probably sometime this summer. It’s more important to get it right than to get it right away.
As soon as people start buying there.
Don’t give AF that much credit. He’s a social media “personality”. He plays on the drama of biotech trading, just as Cramer dramatizes trading for CNBC. Nothing stirs the emotions of investors more than hearing they will win big or lose everything. It’s like gambling. Nobody in the investment media space is out there saying “this lovely investment will return 7% APR for the next 20 years”. That doesn’t sell exposure or get clicks. “This investment will be up 1000% in two years” or “You’ll lose everything with this company!”...that gets people riled up.
Fear is a powerful emotion. Fear of loss or fear of missing out.
I really respect the thinking that this goes to $2-$5 on topline, but I still think the long term potential here is over $20. There’s no reason for management to let go today at under $15 based on our current potential.
Probably just the latest pump and dump biotech Wall St scam. They pump it as the latest and greatest while shorting the hell out of it behind the scenes. Probably did the same with NWBO at $8-$12 back in 2014. They’ll leave it for dead soon.
Alpha
Remember how disillusioned we all were right before ASCO last year. Then, the week before the conference, they released their interim blinded paper. The paper that they had been talking about for 7 months prior. It came out the week before ASCO with no warning.
Well said Ike. ASCO is just another weekend in our captivity to our NWBO investment. Haha.
I’m a believer in the technology and that eventually our vaccine will be approved and used widespread in cancer care. What happens on June 1-2 doesn’t change that. The only thing that changes it is outright trial failure, which is a minimal chance due to the information we have about the blinded data and intent to treat population.
There is one thing I believe LP on...when she said there will be no mercy for the shorts. I believe NWBO will drop positive data and information like the US dropped the A bomb. No warning and in the morning prior to market open. Sit back and watch the effect.
Correction. Patients still alive in the blinded dataset.
I believe they could share SAP being approved, the current number of patients still alive in the DCVAX L blended unblinded dataset, the start of enrollment on a new DC Direct or combo trial, information on a new partnership to advance the pace of trails, or, most importantly, topline data on the L trial. Any or all of this information would cause a positive share price reaction.
It remains a distinct possibility that ASCO comes and goes without topline. But remember, the interim paper was released days prior to ASCO last year. That gives me hope that we’ll get something prior to or at ASCO.
I completely agree with this. I personally theorize that tumor stem cell antigens are critical for the vaccine to be effective. The more removed tissue accumulated for the vaccine lysate, the greater likelihood of getting all the stem cell antigens to present to the DCs. The new dye allows the surgeon to get more tissue.
I believe if this trial were conducted in conjunction with this new tumor dye for surgery, results would be even better.
This is exciting news. Fingers crossed for topline data any day now to allow this technology to move forward to approval.
We’ll know when the street and the funds start buying.
Every increase in outstanding shares should also increase their cash position. While the dilution is frustrating, it’s important that they have the cash to get to approval. We’re not far now and patients deserve this.
Dr Stupp still has 3 thumbs :)
Dr Stupp has 3 thumbs?